Avigilon Video Analytics Patents - What Should A Manufacturer Do?

I have probably read all posts on Avigilon & VA Patents here however it is not clear whether Avigilon has already approached any company with their patent portfolio. Have they? If yes then does somebody have any details?

What strategy do you have for this possible risk? Taking into account that their (OV) patents cover such basic things as a tripwire it looks pretty bad for the industry. Of course, big guys have their own war chests and resources to fight back but what can do small & medium players to protect their customers?

Personally I did not have even one discussion this year without questions regarding possible patent issues on video analytics. Many needs VA but nobody wants to have additional head ache with lawsuits. We have a good team for VA that have been working on it since the early 2000. Our product was good enough to be licensed by for example one more-or-less known VMS vendor. And we have interesting ideas for the future development. Meanwhile it does not look wise to invest in filing patents on our level (expensive and will be way too expensive to use them for protection) and at the same time now it is questionable whether it makes sense to continue development in this area when it became tough (it was tough but now it became much tougher) to sell VA and we have other more prospect products.

Login to read this IPVM discussion.
Why do I need to log in?
IPVM conducts unique testing and research funded by member's payments enabling us to offer the most independent, accurate and in-depth information.

***.
*** *** ***** **** * **** ********* **** ****.
* *** **** ***** **** *** *** ******** ******* ** breach ** ******* *******.
* ***'* ******** *** **** ** *** ** *** *** means ** ***** ***** ****** ** *** ******.
*** *** ** ***** ***** ********* *** **** **** *** permanent ***** ********** **** ***** **** * **** *** **** ache.

***** ******* *** * **** *********** ****** * ***** ******* contacting * ****** *******.
* ***'* ***** ****** ** **** *** **** *** *** help **** **** ****** ** ******* (** *** ******* *********) are ****** *** ********* ** **** **** **** ****.

******

** ******, * **** *** **** ** ******* (***** **** I ** *** ****** ****** ** ****** **** ***).
* ** *** ****** ** **** *** ***** ******** **** but * **** ** **** ** **** ******** ** ***** manufacturers ** **** *****.

"******** *** ******* ********** *** ******* **** ***** ****** *********. Have ****? ** *** **** **** ******** **** *** *******?"

******** *** ******* ******** **** **** *** ******** *** ** some *********. ***** *********** *** **** **** **** ***** ** start **** * ******* ****** ** ********* *** **** ******. I ***'* **** *** ******* ***** **** **** *** ****** for **** '*******' *** **** **** **** **** **** ** look **** ******* ****** *** ** ******* *** **** ******* original ********* **** *** *** ** ******* *** ***** *******.

"** ******, *** **** **** ***** *** *** ****** *** resources ** ***** **** *** **** *** ** ***** & medium ******* ** ******* ***** *********?"

**********, *** *** **** **** *** **** *** ****** ****** when ** **** * *** ***** ***. *** *******, ***** settled, ***** *******, **** *******, ***.

"********* ** **** *** **** **** ** ****** ** ****** patents ** *** *****"

*** ******* ***** ** ****** ** *** ** *** ******, generally, *** *** *** **** *** ****** ** ********'* ******** unless *** ******* **** ** *** ** ********* ***** ********* of **** ******* / ************ **** ******.

"** ** ************ ******* ** ***** ***** ** ******** *********** in **** **** **** ** ****** *****"

** *** **** ** *** ********. ** * ******* ******* (presumably * **********), ** **** ********* **** ****, *** ****** be **** ** ** ****. ** *****, ******** **** *** a *** ** **** ******* *** **** **** *** **** or ***** ***. **** ** **** **** ** ** ***** for ***** ********* **** **** ** ******* ********* *** **** on *** **** *******.

"*** *** ***** **** * **** ********* **** ****."

********. ***** ***** **** ******* ** **** ******** ******* *** pay **** * *** ******* *** ******* (********) ***, ** your ********** ******* *****, ** **** *** ****** **** * difference.

** * *** ** **** *****, *'* ******** **** ******** Avigilon, *** ** * ********** **** *** ** ******, *** then *** **** ** **** ** **** *********, ********, *********, etc.

****: ** ****** ** ***** ********* ***** ** ********** *********, as ****** ******** **** *** ******* **** *** ** **** more ** * **** *****.

***** *** *** **** ******** ****.

********** ******** ****** ********** *** * ** ******** **. *******, it ** * ***-*** **** *** * **** ****** ***** it. ****, *** ***** ******** (***** **) **** ** ***** satisfied ** ** **** ** ********* **** *** ****-***** *******' holder. ** *** **** ****, ********* **** ******* ** * some *** **** ******** **** ********* *******. * ***** ******** some ** ** ******** ***** **: ******* ** ****** ** make * **** **** ******** ** ***. **** ******* **** negative *** *** ****** ***********. ****, ** **** ** ** option ** ** ***** *** **** ** * *** ******* (this **** "*************" *** "******** ********" *** ******* *****), *** deal **** ******** ** **** * ******** *****.

***** ** ** *** ******* ******* ** ** ***** ** a ******* ****** ** ***********.

"** *** **** ****, ********* **** ******* ** * **** way **** ******** **** ********* *******. * ***** ******** **** of ** ******** ***** **: ******* ** ****** ** **** a **** **** ******** ** ***. **** ******* **** ******** for *** ****** ***********."

****??? ** ** *** **** * ****** ******* ********* **** Avigilon, **** **** *** **** **** ***? ******? * ***** that. ****, *****, *****, ****, ********* *** * **** ** other ********* ******* **** ** **********, ***** *** *** ***** by ********.

****** ** ***** ********* ****** *** ****** ********* ******* ********, tell **** ** ** *** ***** ******** * ***** *** invalidate *** *******. *********, ********** * ***** ******* ** ******* and ******.

* *** *** **** *** **** *** ********* :) *** companies ** **** **** ** *** **** *** ********. **** are **** ********** *** ** ** ******* ***** **** ********.

* ** *** **** *** ******* ******* *** *** **** assume **** ***** ** ** ***** **** ******** **** ** consistent *** **** ** **** *** *** **** ********** ** a ********.

* ********** **** **** ************* ** *** ***** ********. *********, based ** ***** ***** ****** ** *********** **** ***** *****, it ** **************.

* **** ** *** *** *** **** ***** **** ** against *** ** *** *** * *******. *** ** **** is ***** ******, ** ** ***** ******.

* ***** ******** **** ** ** ******** ***** **: ******* we ****** ** **** * **** **** ******** ** ***. Most ******* **** ******** *** *** ****** ***********...

*** ***** ****** *** **** ** **** **** ** * formality, **** ****** ********. *** ***** ******?